Compare KeyCorp (KEY) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Pfizer Inc — how do they compare? KeyCorp trades at $19.97 (market cap $21.45B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 7.4× KeyCorp's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Pfizer Inc for 158 Days on average.
| KEY | PFE | |
|---|---|---|
Market Cap | $21.45B | $158.56B |
Volume | 19,450,846 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $23.99 | $29.02 |
52-Week Low | $16.78 | $23.67 |
Typical Hold Time | 66 Days | 158 Days |
Enterprise Value | $34.63B | $210.06B |
Dividend Yield | 4.08% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $20.10, up 1.36% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly earnings beats. Recent corporate actions include a dividend payment scheduled for September 2026 and key executive appointments in wealth and retail banking.
The outlook is supported by analyst consensus with a $25.00 price target and 60.79% buy ratings, though risks include volatile cash flows and competitive pressures. Revenue growth momentum and aggressive share buybacks provide upside potential, but investors should weigh the frozen dividend against peers and monitor interest rate impacts on net interest income.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
